Bristol-Myers Squibb (BMY) vs Novo Nordisk A/S (NVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed Novo Nordisk A/S (NVO) over the past year, gaining 33.8% versus a loss of 36.0%. Over five years, BMY leads with a +2.1% price change compared with -25.4% for NVO. Novo Nordisk A/S is the larger company by market cap ($169.05 billion vs $121.05 billion), about 1.4 times the size.
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (9.0x vs 11.6x for Novo Nordisk A/S). Novo Nordisk A/S offers the higher dividend yield (30.55% vs 4.24%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | NVO |
|---|---|---|
| Share price | $59.26 | $38.30 |
| Market cap | $121.05B | $169.05B |
| 1-day change | -0.54% | +0.30% |
| YTD return | +10.46% | -24.96% |
| 1-year return | +33.77% | -35.95% |
| 5-year return | +2.09% | -25.39% |
| P/E ratio (TTM) | 13.05 | 9.36 |
| Forward P/E | 8.97 | 11.57 |
| EPS (TTM) | $4.54 | $4.09 |
| Dividend yield | 4.24% | 30.55% |
| Annual dividend | $2.51 | $11.70 |
| Revenue (latest FY) | $48.19B | — |
| Revenue growth (YoY) | -0.22% | — |
| Net income (latest FY) | $7.05B | — |
| Gross margin | 71.08% | — |
| Net margin | 14.64% | — |
| 52-week high | $68.64 | $64.16 |
| 52-week low | $42.52 | $35.12 |
| Distance from 52-week high | -13.67% | -40.31% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +11.66% | +20.30% |
| Average volume | 11.30M | 12.64M |
| Shares outstanding | 2.04B | 3.34B |
| Employees | 32,500 | 66,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMY has outperformed NVO by 69.7 percentage points over the past year.
- Bristol-Myers Squibb trades at a higher earnings multiple (13.1x vs 9.4x trailing P/E).
- Novo Nordisk A/S offers a meaningfully higher dividend yield (30.55% vs 4.24%).
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About Novo Nordisk A/S
NVO stock →Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,700 employees
BMY vs NVO FAQ
Which is bigger, Bristol-Myers Squibb or Novo Nordisk A/S?
Novo Nordisk A/S (NVO) is larger, with a market capitalization of $169.05B compared with $121.05B for Bristol-Myers Squibb (BMY).
Which stock has performed better over the past year, BMY or NVO?
BMY returned +33.77% over the past 12 months, compared with -35.95% for NVO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMY or NVO?
NVO has the lower trailing P/E at 9.4, versus 13.1 for BMY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bristol-Myers Squibb or Novo Nordisk A/S?
Novo Nordisk A/S has the higher yield at 30.55%, compared with 4.24% for Bristol-Myers Squibb.
Are Bristol-Myers Squibb and Novo Nordisk A/S in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.